Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792037 | 0.89 | HRH1 (0.47) | HRH1KCNH2NOS1NOS2HRH4 | |
| SCHEMBL29792041 | 0.89 | KCNH2 (0.50) | HRH1KCNH2NOS1NOS2HRH4 | |
| SCHEMBL24618405 | 0.89 | KCNH2 (0.50) | HRH1KCNH2NOS1NOS2HRH4 | |
| SCHEMBL24618443 | 0.89 | HRH1 (0.47) | HRH1KCNH2NOS1NOS2HRH4 | |
| Hydrochloric Acid SCHEMBL30951158 | 0.87 | HRH1 (0.45) | HRH1KCNH2NOS1NOS2HRH4 | |
| SCHEMBL6014618 | 0.85 | NOS1 (0.48) | HRH1KCNH2NOS1NOS2TAAR1 | |
| SCHEMBL30320127 | 0.85 | KCNH2 (0.47) | HRH1KCNH2NOS1NOS2HRH4 | |
| SCHEMBL24618193 | 0.85 | KCNH2 (0.47) | HRH1KCNH2NOS1NOS2HRH4 | |
| SCHEMBL522831 | 0.84 | KCNH2 (0.56) | HRH1KCNH2NOS1NOS2HRH4 | |
| SCHEMBL24617225 | 0.84 | HRH1 (0.47) | HRH1KCNH2NOS1NOS2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092160-A2 | BIFUNCTIONAL PROTEASES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| WO-2022036229-A2 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-20040235814-A1 | Methods to treat conditions mediated by chemokine receptors | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6756391-B2 | CYCLIC POLYAMINES HAVING TOTAL 9-24 MEMBERS WHICH HAVE ACTIVITY IN AGAINST HIV-INFECTED CELLS AS WELL AS OTHER BIOLOGICAL ACTIVITY RELATED TO BINDING OF LIGANDS TO CHEMOKINE RECEPTORS | ANORMED, INC. (CA) | 2004-06-29 | — | — | US | disclosed |
| EP-0739345-B1 | CYCLIC POLYAMINES | ANORMED INC (CA) | 2003-04-09 | — | — | EP | disclosed |
| US-20030018189-A1 | Cyclic polyamines having total 9-24 members which have activity in against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-6506770-B1 | Drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV-infected cells as well | ANORMED, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-1095031-A1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002870-A1 | ANTIVIRAL MACROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2000-01-20 | — | — | WO | disclosed |
| US-5698546-A | Cyclic polyamines | JOHNSON MATTHEY PUBLIC LIMTED COMPANY (GB) | 1997-12-16 | — | — | US | disclosed |
| EP-0739345-A1 | CYCLIC POLYAMINES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995018808-A1 | CYCLIC POLYAMINES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HRH1 688/4885KCNH2 4673/4885NOS1 2529/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HRH1 688/4885KCNH2 4673/4885NOS1 2529/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | HRH1 688/4885KCNH2 4673/4885NOS1 2529/4885 |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | HRH1 688/4885KCNH2 4673/4885NOS1 2529/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | HRH1 3287/4885KCNH2 4739/4885NOS1 974/4885 |
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | FCGR3B, FCGR1A, FCGR2A | HRH1 1751/4885KCNH2 4768/4885NOS1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.